HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $746,690 | +25.6% | 19,547 | +18.8% | 0.00% | 0.0% |
Q2 2023 | $594,734 | +25.8% | 16,457 | +32.2% | 0.00% | 0.0% |
Q1 2023 | $472,897 | -74.5% | 12,449 | -61.8% | 0.00% | -75.0% |
Q4 2022 | $1,854,211 | +56.7% | 32,616 | +9.0% | 0.00% | +33.3% |
Q3 2022 | $1,183,000 | -33.3% | 29,924 | -25.7% | 0.00% | -25.0% |
Q2 2022 | $1,774,000 | +216.8% | 40,300 | +185.3% | 0.00% | +300.0% |
Q1 2022 | $560,000 | -10.5% | 14,125 | -9.4% | 0.00% | 0.0% |
Q4 2021 | $626,000 | -41.4% | 15,589 | -40.6% | 0.00% | -50.0% |
Q3 2021 | $1,068,000 | +71.4% | 26,263 | +92.2% | 0.00% | +100.0% |
Q2 2021 | $623,000 | +12.5% | 13,662 | +3.5% | 0.00% | 0.0% |
Q1 2021 | $554,000 | -78.4% | 13,202 | -78.0% | 0.00% | -85.7% |
Q4 2020 | $2,569,000 | +801.4% | 60,125 | +459.1% | 0.01% | +600.0% |
Q3 2020 | $285,000 | -15.2% | 10,754 | -14.4% | 0.00% | 0.0% |
Q2 2020 | $336,000 | +127.0% | 12,557 | +53.2% | 0.00% | 0.0% |
Q1 2020 | $148,000 | – | 8,199 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
2Xideas AG | 600,799 | $22,950,522 | 2.54% |
BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |